Virtus LifeSci Biotech Clinical Trials ETF


Virtus LifeSci Biotech Clinical Trials ETF

  • Price (USD)27.28
  • Today's Change0.070 / 0.26%
  • Shares traded708.00
  • 1 Year change-22.23%
Data delayed at least 15 minutes, as of Sep 20 2019 21:10 BST.
More ▼

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Small
Investment Style: Growth
Morningstar categoryHealth
Launch date16 Dec 2014
Price currencyUSD
DomicileUnited States
Manager & start date
Matthew Brown
14 Aug 2017
Seth Kadushin
14 Aug 2017
Pricing frequencyDaily
Total net assets
25.22m USD
As of Aug 31 2019
Net expense ratio0.79%
Front end load--
Deferred load--
Maximum Redemption Fee--
Min. initial investment--
Min. additional investment--
Initial IRA--
Additional IRA--
Available for saleUnited States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Allakos Inc
G1 Therapeutics Inc
Deciphera Pharmaceuticals Inc
Krystal Biotech Inc
Achillion Pharmaceuticals Inc
Per cent of portfolio in top 5 holdings: 9.48%
Top 10 Holdings


Asset type

Asset type

US stock93.67%
Non-US stock6.05%
US bond0.00%
Non-US bond0.00%

Top 5 sectors

Fixed income
Basic Materials1.02%

Top 5 regions

United States93.67%
United Kingdom3.81%
Emerging Asia1.30%
Developed Asia0.95%
Sector and region weightings are calculated using only long position holdings of the portfolio.
Intra-day ETF pricing data provided by Refinitiv
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on is subject to the FT Terms & Conditions
All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2019
All Rights reserved
© 2019 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.